Comparative Effectiveness of Propranolol Versus Risperidone in Children with Autism Spectrum Disorder
Open Access
- 29 September 2026
- journal article
- Published by SAGE Publications in Journal of Indian Association for Child and Adolescent Mental Health
- Vol. 22 (4) , 338-351
Abstract
Background: Autism spectrum disorder (ASD) is a neurodevelopmental condition, affecting one in every 68 children in India. It is associated with social communication deficits and restricted, repetitive behaviors, for which pharmacological options are currently limited. Risperidone demonstrates modest efficacy in core domains and has an adverse metabolic profile. Propranolol, a beta-adrenergic antagonist, is an emerging candidate that may modulate autonomic dysregulation implicated in ASD. Methods: Based on DSM-5 criteria, 55 children (4–12 years), diagnosed with ASD, were randomized to receive either propranolol ( n = 30) or risperidone ( n = 30), in a prospective, 12-week, open-label trial, conducted at a tertiary center in India. Indian Scale for Assessment of Autism (ISAA), Clinical Global Impressions Scale (Clinical Global Impressions-improvement Scale), Spence Children’s Anxiety Scale, Social Responsiveness Scale, Second Edition, and Aberrant Behavior Checklist were used to measure outcomes at baseline, 4, 8, and 12 weeks, along with side effects monitoring. Results: Significant improvement was seen on ISAA in both groups, with no between-group differences at 12 weeks ( P = .11). Risperidone exhibited greater improvements in irritability and hyperactivity, whereas propranolol was associated with more pronounced change in the domains of social phobia, social withdrawal and generalized anxiety ( P < .05). The risperidone group was associated with a significant increase in weight at the end of 12 weeks, and the propranolol group was associated with irritability and one episode of syncope. Conclusion: The present study provides preliminary exploratory evidence suggesting that propranolol may be a candidate for further evaluation in children with ASD, particularly those with prominent anxiety and social withdrawal. Risperidone demonstrated greater efficacy for behavioral symptoms such as irritability and hyperactivity. These findings are hypothesis-generating and require replication in adequately powered, double-blind, placebo-controlled trials before any firm clinical conclusions can be drawn.Keywords
This publication has 33 references indexed in Scilit:
- Randomized controlled trial of propranolol on social communication and anxiety in children and young adults with autism spectrum disorderPsychopharmacology, 2023
- Brief Report: Testing the Psychometric Properties of the Spence Children’s Anxiety Scale (SCAS) and the Screen for Child Anxiety Related Emotional Disorders (SCARED) in Autism Spectrum DisorderJournal of Autism and Developmental Disorders, 2020
- The Role of the Noradrenergic System in Autism Spectrum Disorders, Implications for TreatmentSeminars in Pediatric Neurology, 2020
- The reliability and validity of the social responsiveness scale to measure autism symptomology in Vietnamese childrenAutism Research, 2019
- Weight Gain and Metabolic Consequences of Risperidone in Young Children With Autism Spectrum DisorderJournal of the American Academy of Child & Adolescent Psychiatry, 2016
- Effects of propranolol on conversational reciprocity in autism spectrum disorder: a pilot, double-blind, single-dose psychopharmacological challenge studyPsychopharmacology, 2016
- Validity of the Aberrant Behavior Checklist in Children with Autism Spectrum DisorderJournal of Autism and Developmental Disorders, 2013
- Effect of Propranolol on Functional Connectivity in Autism Spectrum Disorder—A Pilot StudyBrain Imaging and Behavior, 2010
- Atypical eye contact in autism: Models, mechanisms and developmentNeuroscience & Biobehavioral Reviews, 2009
- Oral propranolol treatment in infants and childrenThe Journal of Pediatrics, 1978